Bionano Genomics- Warrants (21/08/2023) Profit Margin

As of the most recent data (March 2026), BNGOW shows a profit margin of -109.95%. That compares with -294.05% in the prior-year period — up 62.6% year over year. That is below the Healthcare sector average of 14.34%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BNGOW's profit margin is now -109.95% (was -294.05%) — a 62.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Bionano Genomics- Warrants (21/08/2023) is outperforming or lagging.

The Healthcare sector average profit margin is about 14.34%. Bionano Genomics- Warrants (21/08/2023) is at -109.95%, which is lower that average. That is roughly 866.4% below the sector mean. Use the comparison chart on this page to see how BNGOW stacks up against individual peers as well.

That compares with -294.05% in the prior-year period — up 62.6% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Bionano Genomics- Warrants (21/08/2023) with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Bionano Genomics- Warrants (21/08/2023)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -109.95%) with ownership activity and broader fundamentals.